<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-0011</journal-id>
<journal-title><![CDATA[Revista de la Facultad de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[rev.fac.med.]]></abbrev-journal-title>
<issn>0120-0011</issn>
<publisher>
<publisher-name><![CDATA[Universidad Nacional de Colombia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-00112018000400551</article-id>
<article-id pub-id-type="doi">10.15446/revfacmed.v66n4.58933</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Clinical inertia in insulin prescription for patients with type 2 diabetes mellitus at a primary health care institution of Cartagena, Colombia]]></article-title>
<article-title xml:lang="es"><![CDATA[Inercia clínica en la prescripción de insulina en pacientes con diabetes mellitus tipo 2 de una institución de baja complejidad en Cartagena de Indias, Colombia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Llinás-Castro]]></surname>
<given-names><![CDATA[Rodolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alvis-Estrada]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Durán-Lengua]]></surname>
<given-names><![CDATA[Marlene]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Local Cartagena de Indias  ]]></institution>
<addr-line><![CDATA[Cartagena de Indias ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Cartagena  ]]></institution>
<addr-line><![CDATA[Cartagena ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Cartagena  ]]></institution>
<addr-line><![CDATA[Cartagena ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>66</volume>
<numero>4</numero>
<fpage>551</fpage>
<lpage>555</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-00112018000400551&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-00112018000400551&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-00112018000400551&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Evidence has demonstrated clinical or prescriptive inertia along with an increased prescription of insulin, causing a delay in the change of prescription.  Objective: To determine the prescription pattern and clinical inertia of insulin use in the treatment of patients with type 2 diabetes mellitus (DM2) enrolled in a diabetes program at a primary health care institution of Cartagena, Colombia.  Materials and methods: Pharmacoepidemiology study that addresses drug utilization based on data collected through a review of medical records of 331 patients with DM2, aged 18 and older, who had at least 6 months of control.  Results: 64.4% of patients were treated with long-acting insulin analogues and 18.4% used insulin; 52.7% of the patients in which insuline use was required did not have a prescription of this drug.  Conclusions: There is clinical inertia related to insulin prescription. Strategies should be implemented to overcome prescriptive inertia for people with DM2 in order to achieve therapeutic goals earlier and effectively prevent the development and progression of chronic complications.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción. Paralelo al aumento de la prescripción de la insulina se ha demostrado la inercia clínica o prescriptiva, de tal manera que la demora en cambiar la prescripción es prolongada.  Objetivo. Determinar el patrón de prescripción y la inercia clínica en la utilización de insulina al momento de estar indicada en el tratamiento de los pacientes con diabetes mellitus tipo 2 (DM2) que acuden a un programa de diabetes en una institución de baja complejidad de Cartagena, Colombia.  Materiales y métodos. Estudio de farmacoepidemiología dirigido al campo de los estudios de utilización de medicamentos que se basó en datos recogidos mediante la revisión de historias clínicas de 331 pacientes con DM2, mayores de 18 años y que tuvieran mínimo 6 meses de control.  Resultados. El 18.4% de los pacientes utilizaron insulina. 64.4% fueron tratados con análogos de insulinas de acción prolongada. 52.7% de los pacientes con indicación de insulina no tenían prescrito el fármaco.  Conclusiones. Existe inercia clínica para la prescripción de insulina. Se deben implementar estrategias que superen la inercia prescriptiva para que las personas con DM2 alcancen tempranamente las metas terapéuticas y prevengan de manera efectiva el desarrollo y la progresión de complicaciones crónicas.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Diabetes Mellitus Type 2]]></kwd>
<kwd lng="en"><![CDATA[Insulin]]></kwd>
<kwd lng="en"><![CDATA[Therapeutic Uses]]></kwd>
<kwd lng="en"><![CDATA[Drug Prescriptions]]></kwd>
<kwd lng="en"><![CDATA[Drug-related side effects and adverse reactions (MeSH)]]></kwd>
<kwd lng="es"><![CDATA[Diabetes mellitus tipo 2]]></kwd>
<kwd lng="es"><![CDATA[Insulina]]></kwd>
<kwd lng="es"><![CDATA[Indicación Terapéutica]]></kwd>
<kwd lng="es"><![CDATA[Prescripción de medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Inercia]]></kwd>
<kwd lng="es"><![CDATA[Efectos colaterales y reacciones adversas relacionados con medicamentos (DeCS)]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>International Diabetes Federation</collab>
<source><![CDATA[Atlas de la diabetes de la IDF]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Brussels ]]></publisher-loc>
<publisher-name><![CDATA[IDF]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gæde]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Valentine]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tucker]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Lammert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Parving]]></surname>
<given-names><![CDATA[H-H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of intensified versus conventional multi-factorial intervention in type 2 diabetes: results and projections from the steno-2 study]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2008</year>
<volume>31</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1510-5</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>Organización Panamericana de la Salud</collab>
<source><![CDATA[Guías ALAD de diagnóstico, control y tratamiento de la Diabetes Mellitus Tipo 2]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Washington D.C. ]]></publisher-loc>
<publisher-name><![CDATA[OPS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>Ministerio de Sanidad, Servicios Sociales e Igualdad</collab>
<source><![CDATA[Informe de Utilización de Medicamentos U/AN/V1/03092015 Utilización de medicamentos antidiabéticos en España durante el periodo 2000-2014]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Kapor]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lank]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Willan]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Houston]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical inertia in patients with T2DM requiring insulin in family practice]]></article-title>
<source><![CDATA[Can Fam Physician]]></source>
<year>2010</year>
<volume>56</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>e418-24</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Pathan]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ji]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yeung]]></surname>
<given-names><![CDATA[VT]]></given-names>
</name>
<name>
<surname><![CDATA[Chadha]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Suastika]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[First in-sulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia]]></article-title>
<source><![CDATA[J Diabetes]]></source>
<year>2011</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>208-16</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Wetmore]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Faulds]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Webster-Bogaert]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Type 2 diabetes in family practice. Room for improvement]]></article-title>
<source><![CDATA[Can Fam Physician]]></source>
<year>2003</year>
<volume>49</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>778-85</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yale]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Dempsey]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gerstein]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Can family physicians help patients initiate basal insulin therapy successfully? Randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial]]></article-title>
<source><![CDATA[Can Fam Physician]]></source>
<year>2008</year>
<volume>54</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>550-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gagliardino]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Costa-Gil]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Faingold]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Litwak]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fuente]]></surname>
<given-names><![CDATA[GV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulina y control de la diabetes en la Argentina]]></article-title>
<source><![CDATA[Medicina (B Aires)]]></source>
<year>2013</year>
<volume>73</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>520-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peyrot]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Lauritzen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Skovlund]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Snoek]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Matthews]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2005</year>
<volume>28</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2673-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Korytkowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[When oral agents fail: practical barriers to starting insulin]]></article-title>
<source><![CDATA[Int J Obes Relat Metabc Disord]]></source>
<year>2002</year>
<volume>26</volume>
<numero>^sSuppl 3</numero>
<issue>^sSuppl 3</issue>
<supplement>Suppl 3</supplement>
<page-range>S18-24</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Funnell]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overcoming barriers to the initiation of insulin therapy]]></article-title>
<source><![CDATA[Clinical Diabetes]]></source>
<year>2007</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>36-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shafiee]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mohajeri-Tehrani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pajouhi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Larijani]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The importance of hypoglycemia in diabetic patients]]></article-title>
<source><![CDATA[Diabetes Metab Disord]]></source>
<year>2012</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Hux]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Laupacis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zinman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Van Walraven]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical inertia in response to inadequate glycemic control do specialists differ from primary care physicians?]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2005</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>600-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cox]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Ferner]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prescribing errors in diabetes]]></article-title>
<source><![CDATA[British Journal of Diabetes and Vascular Disease]]></source>
<year>2009</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>84-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faus-Dáder]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Romero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La Atención Farmacéutica en farmacia comunitaria: evolución de conceptos, necesidades de formación, modalidades y estrategias para su puesta en marcha]]></article-title>
<source><![CDATA[Pharm Care Esp]]></source>
<year>1999</year>
<volume>1</volume>
<page-range>52-61</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[American Diabetes Assciation. 1. Promoting Health and Reducing Disparities in Populations]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2017</year>
<volume>40</volume>
<numero>^sSuppl 1</numero>
<issue>^sSuppl 1</issue>
<supplement>Suppl 1</supplement>
<page-range>S6-S10</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garber]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Abrahamson]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Barzilay]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Blonde]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bloomgarden]]></surname>
<given-names><![CDATA[ZT]]></given-names>
</name>
<name>
<surname><![CDATA[Bush]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2017 Executive Summary]]></article-title>
<source><![CDATA[Endocrine Practice]]></source>
<year>2017</year>
<volume>23</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>207-38</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Home]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Riddle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cefalu]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bretzel]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[del Prato]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin therapy in people with type 2 diabetes: opportunities and challenges?]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2014</year>
<volume>37</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1499-508</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maqueda-Villaizán]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Peña-Cortés]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[García-Palomo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchón-Rodríguez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Luque-Fernández]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[López-López]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pautas de Insulinización en Diabetes Mellitus]]></article-title>
<source><![CDATA[Boletín Farmaco terapéutico de Castilla-La Mancha]]></source>
<year>2009</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<collab>Colombia. Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Guía de práctica clínica para el diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años. Guía para profesionales de la salud 2015 - Guía No. GPC-2015-51]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Bogotá D.C. ]]></publisher-loc>
<publisher-name><![CDATA[Min Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petznick]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin management of type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Am Fam Physician]]></source>
<year>2011</year>
<volume>84</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>183-90</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garber]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Abrahamson]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Barzilay]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Blonde]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bloomgarden]]></surname>
<given-names><![CDATA[ZT]]></given-names>
</name>
<name>
<surname><![CDATA[Bush]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary]]></article-title>
<source><![CDATA[Endocr Pract]]></source>
<year>2016</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>84-113</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="book">
<collab>Ministerio de la Protección Social</collab>
<article-title xml:lang=""><![CDATA[Guía 17. Guía de atención de la diabetes mellitus tipo 2]]></article-title>
<source><![CDATA[Guías de promoción de la salud y prevención de enfermedades en la salud pública]]></source>
<year>2007</year>
<page-range>359-439</page-range><publisher-loc><![CDATA[Bogotá D.C. ]]></publisher-loc>
<publisher-name><![CDATA[MPS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae]]></article-title>
<source><![CDATA[Postgrad Med]]></source>
<year>2012</year>
<volume>124</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>90-7</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holman]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Paul]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Bethel]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Matthews]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Neil]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[10-year follow-up of intensive glucose control in type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2008</year>
<volume>359</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1577-89</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maedler]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Donath]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#946;-Cells in type 2 diabetes: a loss of function and mass]]></article-title>
<source><![CDATA[Horm Res]]></source>
<year>2004</year>
<volume>62</volume>
<numero>Suppl 3</numero>
<issue>Suppl 3</issue>
<page-range>67-73</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weng]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of intensive insulin therapy on p-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2008</year>
<volume>371</volume>
<numero>9626</numero>
<issue>9626</issue>
<page-range>1753-60</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villegas-Perrasse]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Abad]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Faciolince]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Maya]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Parra]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El control de la diabetes mellitus y sus complicaciones en Medellín, Colombia, 2001-2003]]></article-title>
<source><![CDATA[Rev Panam Salud Pública]]></source>
<year>2006</year>
<volume>20</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>393-402</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Moncada-Escobar]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Mesa-Escobar]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Patrones de prescripción de antidiabéticos en un grupo de pacientes colombianos]]></source>
<year>2007</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>124-31</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pellegrini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Belfiglio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Berardis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Franciosi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Di Nardo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Greenfield]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of organizational factors in poor blood pressure control in patients with type 2 diabetes: the QuED Study Group-quality of care and outcomes in type 2 diabetes]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2003</year>
<volume>163</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>473-80</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Gutiérrez]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tiempo para el inicio de insulina y factores asociados al cambio de tratamiento en pacientes diabéticos tipo 2]]></article-title>
<source><![CDATA[Revista Médica de Risaralda]]></source>
<year>2015</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alba]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Bastidas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vivas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de control glucémico y factores relacionados en pacientes con diabetes mellitus tipo 2 del Hospital Universitario de San Ignacio, Bogotá, Colombia]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>2009</year>
<volume>145</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>469-74</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mavrogiannaki]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Migdalis]]></surname>
<given-names><![CDATA[IN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-acting basal insulin analogs: latest developments and clinical usefulness]]></article-title>
<source><![CDATA[Ther Adv Chronic Dis]]></source>
<year>2012</year>
<volume>3</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>249-57</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mancera-Romero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hormigo-Pozo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Arquero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Baca-Osorio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aparicio-Cervantes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz-González]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilización de fármacos hipoglucemiantes en el ámbito de la atención primaria de Málaga durante los años 2008-2012]]></article-title>
<source><![CDATA[SEMERGEN-Medicina de Familia]]></source>
<year>2014</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-11</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peralta-Pedrero]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Valdivia-Ibarra]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Manzano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Medina-Beltrán]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Cordero-Guillén]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Baca-Zúñiga]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía de práctica clínica. Prescripción farmacológica en el adulto mayor]]></article-title>
<source><![CDATA[Rev Med Inst Mex Seguro Soc]]></source>
<year>2013</year>
<volume>51</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>228-39</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harper]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Clement]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Goldenberg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Main]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Retnakaran]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacologic management of type 2 diabetes. Can J Diabetes]]></article-title>
<source><![CDATA[]]></source>
<year>2013</year>
<volume>37</volume>
<numero>^sSuppl 1</numero>
<issue>^sSuppl 1</issue>
<supplement>Suppl 1</supplement>
<page-range>S61-8</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvert]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[McManus]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Freemantle]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study]]></article-title>
<source><![CDATA[Br J Gen Pract]]></source>
<year>2007</year>
<volume>57</volume>
<numero>539</numero>
<issue>539</issue>
<page-range>455-60</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<collab>UK Prospective Diabetes Study Group</collab>
<article-title xml:lang=""><![CDATA[UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>1998</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>87-92</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guidoni]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Borges]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Od]]></surname>
<given-names><![CDATA[Freitas]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prescription patterns for diabetes mellitus and therapeutic implications: a population-based analysis]]></article-title>
<source><![CDATA[Arq Bras Endocrinol Metabol]]></source>
<year>2012</year>
<volume>56</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>120-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
